Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
35.64
+0.22 (0.62%)
At close: Sep 17, 2025, 4:00 PM EDT
35.71
+0.07 (0.20%)
After-hours: Sep 17, 2025, 7:02 PM EDT
Royalty Pharma Revenue
Royalty Pharma had revenue of $578.67M in the quarter ending June 30, 2025, with 7.71% growth. This brings the company's revenue in the last twelve months to $2.31B, up 3.02% year-over-year. In the year 2024, Royalty Pharma had annual revenue of $2.26B, down -3.86%.
Revenue (ttm)
$2.31B
Revenue Growth
+3.02%
P/S Ratio
6.77
Revenue / Employee
$23,285,283
Employees
99
Market Cap
20.78B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.26B | -90.98M | -3.86% |
Dec 31, 2023 | 2.35B | 117.34M | 5.24% |
Dec 31, 2022 | 2.24B | -52.25M | -2.28% |
Dec 31, 2021 | 2.29B | 167.11M | 7.87% |
Dec 31, 2020 | 2.12B | 308.10M | 16.98% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
RPRX News
- 5 days ago - Royalty Pharma: Investor Day Upside - Seeking Alpha
- 6 days ago - Royalty Pharma Plc (RPRX) Investor Day 2025 Call (Transcript) - Seeking Alpha
- 6 days ago - Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company's Plans to Drive Value Creation - GlobeNewsWire
- 7 days ago - Royalty Pharma Announces Release of Deloitte's Report on the Biopharma Royalty Market - GlobeNewsWire
- 8 days ago - Royalty Pharma Plc (RPRX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 13 days ago - Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference - GlobeNewsWire
- 15 days ago - Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes - GlobeNewsWire
- 15 days ago - Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million - GlobeNewsWire